Skip to Main content Skip to Navigation

Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells

Abstract : Epithelial ovarian cancers are insidious pathologies that give a poor prognosis due to their late discovery and the increasing emergence of chemoresistance. Development of small pharmacological anticancer molecules remains a major challenge. Ribavirin, usually used in the treatment of hepatitis C virus infections and more recently few cancers, has been a suggestion. However, Ribavirin has many side-effects, suggesting that the synthesis of analogs might be more appropriate. We have investigated the effect of a Ribavirin analog, SRO-91, on cancer cell behavioral characteristics considered as some of the hallmarks of cancer. Two human ovarian adenocarcinoma cell lines (SKOV3 and IGROV1) and normal cells (mesothelial and fibroblasts) have been used to compare the effects of SRO-91 with those of Ribavirin on cell behavior underlying tumor cell dissemination. SRO-91, like Ribavirin, inhibits proliferation, migration, clonogenicity and spheroids formation of cancer cells. Unlike Ribavirin, SRO-91 is preferentially toxic to cancer compared with normal cells. An in vitro physiologically relevant model showed that SRO-91, like Ribavirin or cisplatin, inhibits cancer cell implantation onto peritoneal mesothelium. In conclusion, SRO-91 analog effects on tumor dissemination and its safety regarding non-cancerous (normal) cells are encouraging findings a promising drug for the treatment of ovarian cancer.
Complete list of metadatas

Cited literature [42 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02429497
Contributor : Myriam Bodescot <>
Submitted on : Monday, January 6, 2020 - 4:35:49 PM
Last modification on : Thursday, March 5, 2020 - 4:20:52 PM

File

journal.pone.0225860.pdf
Publication funded by an institution

Identifiers

Citation

Anaïs Wambecke, Carine Laurent-Issartel, Johanne Leroy-Dudal, Florence Giffard, Fanny Cosson, et al.. Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells. PLoS ONE, Public Library of Science, 2019, 14 (12), pp.e0225860. ⟨10.1371/journal.pone.0225860⟩. ⟨inserm-02429497⟩

Share

Metrics

Record views

104

Files downloads

55